Biopharma News

Nov 16, 2017
By BioPharm International Editors
As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.
Nov 16, 2017
By BioPharm International Editors
Bayer will make a $400-million upfront payment to develop and commercialize two anti-cancer compounds in Loxo Oncology’s portfolio.
Nov 16, 2017
By BioPharm International Editors
The entities announced that they will partner to improve access to cancer treatments and diagnostics in Ethiopia, Uganda, and Tanzania.
Nov 13, 2017
By BioPharm International Editors
The company has appointed Albert Bourla, PhD, as its new COO.
Nov 10, 2017
By BioPharm International Editors
The company expects to commercially launch the new vaccine in the US in the first quarter of 2018.
Nov 10, 2017
By BioPharm International Editors
The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for AstraZeneca’s benralizumab, a monoclonal antibody for treating severe asthma.
Nov 03, 2017
By BioPharm International Editors
The agency gave Breakthrough Therapy Designation to GSK’s GSK2857916 monotherapy for the treatment of patients with multiple myeloma who have failed at least three prior lines of therapy.
Nov 02, 2017
By BioPharm International Editors
The companies will collaborate to develop and manufacture Grid’s lead therapeutic candidate for the treatment of solid tumors.
Oct 27, 2017
By BioPharm International Editors
AbbVie will pay a $205-million upfront payment and have the option to develop and commercialize two antibody targets globally.
Oct 27, 2017
By BioPharm International Editors
As part of the $900-million deal, Incyte will pay $150 million upfront to develop and commercialize an anti-PD-1 drug candidate from biopharmaceutical company, MacroGenics.
native1_300x100
lorem ipsum